AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
AnaptysBio, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0026ZDHT8
48.73▲ 0.63 (1.31%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
48.10
Day's Range
47.05 – 48.89
52-Week Range
30.27 – 73.30
Volume
455.6K
Avg Volume
561.1K
Share Statistics
Shares Outstanding
Employees
104
Exchange
XNAS
Listed
2017-01-26
Share count as of September 16, 2026

AnaptysBio, Inc. Common Stock (ANAB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about AnaptysBio, Inc. Common Stock (ANAB)
What is AnaptysBio, Inc. Common Stock's Market Cap?
AnaptysBio, Inc. Common Stock's Market Cap is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Enterprise Value?
AnaptysBio, Inc. Common Stock's Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Trailing P/E?
AnaptysBio, Inc. Common Stock's Trailing P/E is 7.4×, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Price / Sales?
AnaptysBio, Inc. Common Stock's Price / Sales is 6.1×, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's EV / Revenue?
AnaptysBio, Inc. Common Stock's EV / Revenue is 5.6×, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's EV / EBITDA?
AnaptysBio, Inc. Common Stock's EV / EBITDA is 6.1×, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Revenue (TTM)?
AnaptysBio, Inc. Common Stock's Revenue (TTM) is $237.6M, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Net Income (TTM)?
AnaptysBio, Inc. Common Stock's Net Income (TTM) is $195.7M, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's EBITDA?
AnaptysBio, Inc. Common Stock's EBITDA is $215.8M, based on as-reported figures from SEC (XBRL) filings.
What is AnaptysBio, Inc. Common Stock's Diluted EPS (TTM)?
AnaptysBio, Inc. Common Stock's Diluted EPS (TTM) is 6.55, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ANABAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Collaboration revenue
YoY growth-8.0%+151.1%+154.3%+102.9%
Operating expenses:
Research and development—
General and administrative
Total operating expenses
% of revenue235.5%-127.2%54.5%217.5%
(Loss) income from operations
% of revenue-135.5%227.2%45.5%-117.5%
Other income (expense), net:
Interest income
Non-cash interest expense for the sale of future royalties
Other (expense) income, net—
Total other income (expense), net
(Loss) income before income taxes
Benefit (provision) for income taxes
Net income (loss)
% of revenue-206.9%45.8%19.8%-173.5%
Net income (loss) per common share - basic
Net income (loss) per common share - diluted